Laboratorios Farmaceuticos Rovi, S.A. (LABFF) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Laboratorios Farmaceuticos Rovi, S.A. (LABFF) trades at $90.61 with AI Score 46/100 (Grade C). Laboratorios Farmaceuticos Rovi, S. A. is a Spanish pharmaceutical company engaged in the research, development, production, and sale of pharmaceutical products. Market cap: $4.63B, Sector: Healthcare.
Price as of Jul 23, 2026 · Last analyzed: Mar 17, 2026Analyst Coverage for LABFF: LABFF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates LABFF against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
LABFF: 2/3 scored disciplines lean bullish. Dominant signal: Ken Griffin bullish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Laboratorios Farmaceuticos Rovi, S.A. (LABFF) Healthcare & Pipeline Overview
Laboratorios Farmaceuticos Rovi, S.A. is a Spanish biopharmaceutical company specializing in the development, manufacturing, and marketing of proprietary and licensed pharmaceutical products, including low-molecular-weight heparins and contrast agents, while also providing contract manufacturing services, positioning it as a diversified player in the global healthcare market.
What Is the Investment Thesis for LABFF?
Laboratorios Farmaceuticos Rovi, S.A. presents a compelling investment case based on its diversified revenue streams from both proprietary pharmaceutical products and contract manufacturing services. The company's focus on specialized medications, such as low-molecular-weight heparins and contrast agents, provides a stable revenue base. The collaboration with Moderna for mRNA COVID-19 vaccine manufacturing represents a significant growth catalyst. With a market capitalization of $4.63B and a P/E ratio of 22.6, Rovi's valuation reflects its growth potential. Key risks include competition from generic drug manufacturers and potential regulatory changes in the pharmaceutical industry. The company's strong gross margin of 63.8% and a profit margin of 18.9% indicate efficient operations and profitability.
Based on FMP financials and quantitative analysis
LABFF Key Highlights
- Market capitalization of $4.63B reflects investor confidence in Rovi's growth prospects.
- P/E ratio of 22.6 indicates a premium valuation, suggesting expectations of future earnings growth.
- Gross margin of 63.8% demonstrates strong pricing power and efficient cost management.
- Profit margin of 18.9% highlights Rovi's ability to generate profits from its revenue streams.
- Dividend yield of 1.17% provides a modest income stream for investors.
Who Are LABFF's Competitors?
LABFF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| AKBLF ALK-Abelló A/S | $37.91 | +0.00% | $7.63B | 55 |
| CAMRF Camurus AB (publ) | $58.51 | +0.00% | $3.48B | 63 |
| CSMYF COSMOS Pharmaceutical Corporation | $37.06 | +0.00% | $2.94B | 52 |
| CZMWF Carl Zeiss Meditec AG | $33.50 | +0.00% | $2.93B | 49 |
| GNNSF Genscript Biotech Corporation | $1.82 | +0.00% | $3.98B | 58 |
| VCYT Veracyte, Inc. | $57.88 | -0.22% | $4.62B | 99 |
| CAI Caris Life Sciences, Inc. | $15.65 | +1.76% | $4.42B | 79 |
| ACAD ACADIA Pharmaceuticals Inc. | $24.83 | -0.52% | $4.25B | 80 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are LABFF's Key Strengths?
- Diversified product portfolio
- Strong contract manufacturing capabilities
- Established presence in Europe
- Collaboration with Moderna
What Are LABFF's Weaknesses?
- Reliance on a limited number of key products
- Exposure to generic competition
- Limited geographic diversification
- Dependence on contract manufacturing agreements
What Could Drive LABFF Stock Higher?
- Continued demand for Rovi's proprietary pharmaceutical products, including low-molecular-weight heparins and contrast agents.
- Expansion of contract manufacturing services with existing and new pharmaceutical partners.
- Revenue generation from the collaboration with Moderna for manufacturing mRNA COVID-19 vaccine candidate.
- Potential regulatory approvals for new pharmaceutical products in development.
- Expansion into new geographic markets, particularly in emerging economies.
What Are the Key Risks for LABFF?
- Competition from generic drug manufacturers eroding market share for key products.
- Regulatory changes in the pharmaceutical industry impacting pricing and market access.
- Economic downturns reducing healthcare spending and demand for pharmaceutical products.
- Patent expirations leading to decreased revenue from proprietary drugs.
- Dependence on contract manufacturing agreements, which can be terminated or renegotiated.
What Are the Growth Opportunities for LABFF?
- Expansion of Contract Manufacturing Services: Rovi's contract manufacturing business represents a significant growth opportunity. The global pharmaceutical contract manufacturing market is projected to reach $228.17 billion by 2028, growing at a CAGR of 6.7%. By leveraging its manufacturing capabilities and expertise, Rovi can secure additional contracts from pharmaceutical companies seeking to outsource production.
- Increased Demand for Biosimilars: The rising demand for biosimilars, driven by cost containment pressures and patent expirations of blockbuster drugs, presents a growth opportunity for Rovi. The global biosimilars market is projected to reach $107.63 billion by 2029, growing at a CAGR of 20.7%. Rovi's Enoxaparin biosimilar Becat positions it to capitalize on this trend.
- Geographic Expansion: Rovi has the opportunity to expand its geographic presence beyond its current markets in Spain, the European Union, and OECD countries. Entering new markets, particularly in emerging economies with growing healthcare expenditures, can drive revenue growth. This expansion could involve direct sales, partnerships, or acquisitions.
- Development of Novel Pharmaceutical Products: Investing in research and development to create novel pharmaceutical products can drive long-term growth for Rovi. Focusing on therapeutic areas with unmet medical needs, such as cardiovascular disease, oncology, and neurology, can lead to the development of innovative drugs with high market potential. This strategy requires significant investment and carries inherent risks.
- Collaboration with Moderna: The collaboration with Moderna for manufacturing mRNA COVID-19 vaccine candidate represents a significant growth opportunity for Rovi. As the demand for COVID-19 vaccines continues, Rovi can generate substantial revenue from its manufacturing agreement. Furthermore, this collaboration could lead to additional partnerships with Moderna or other biotechnology companies in the future.
What Opportunities Does LABFF Have?
- Expansion into new geographic markets
- Development of novel pharmaceutical products
- Increased demand for biosimilars
- Growth in the contract manufacturing market
What Threats Does LABFF Face?
- Competition from generic drug manufacturers
- Regulatory changes in the pharmaceutical industry
- Economic downturns
- Patent expirations
What Are LABFF's Competitive Advantages?
- Specialized Product Portfolio: Rovi's focus on specialized medications, such as low-molecular-weight heparins and contrast agents, creates a niche market position.
- Contract Manufacturing Expertise: Rovi's expertise in contract manufacturing provides a competitive advantage.
- Established Relationships: Rovi has established relationships with wholesalers, doctors, nursing staff, pharmacists, and patients.
- Collaboration with Moderna: The collaboration with Moderna provides access to innovative mRNA technology and manufacturing opportunities.
What Does LABFF Do?
Laboratorios Farmaceuticos Rovi, S.A., founded in 1946 and headquartered in Madrid, Spain, is a pharmaceutical company engaged in the research, development, production, and commercialization of pharmaceutical products. The company operates in Spain, the European Union, OECD countries, and internationally. Rovi's core business revolves around both proprietary pharmaceutical products and contract manufacturing services for other pharmaceutical companies. Its product portfolio includes Hibor and Enoxaparin biosimilar Becat, low-molecular-weight heparins used to prevent and treat venous thromboembolic disease. Other key products include Neparvis for chronic heart failure, Absorcol for hypercholesterolemia, bronchodilators Hirobriz Breezhaler and Ulunar Breezhaler for chronic obstructive pulmonary disease, and Volutsa for benign prostatic hyperplasia. Additionally, Rovi markets hospital products for imaging diagnosis, such as Iomeron and Iopamiro for computed tomography, Multihance and Prohance for magnetic resonance imaging, and Sonovue for ultrasounds. The company also offers contract manufacturing services, producing prefilled syringes, vials, suppositories, tablets, hard capsules, and sachets for other pharmaceutical companies. Rovi serves a diverse customer base, including wholesalers, doctors, nursing staff, pharmacists, and patients. The company has a collaboration with Moderna, Inc. for manufacturing mRNA COVID-19 vaccine candidate.
What Products and Services Does LABFF Offer?
- Researches and develops pharmaceutical products.
- Produces and sells pharmaceutical products in Spain, the EU, OECD countries, and internationally.
- Distributes products licensed from other laboratories.
- Manufactures low-molecular-weight heparins to prevent and treat venous thromboembolic disease.
- Markets products for the treatment of chronic heart failure and hypercholesterolemia.
- Offers products for the treatment of chronic obstructive pulmonary diseases and benign prostatic hyperplasia.
- Provides hospital products for imaging diagnosis.
- Offers contract-manufacturing services to other pharmaceutical companies.
How Does LABFF Make Money?
- Develops and manufactures proprietary pharmaceutical products.
- Generates revenue through the sale of its own branded products.
- Provides contract manufacturing services to other pharmaceutical companies.
- Collects fees for manufacturing pharmaceutical products on behalf of other companies.
What Industry Does LABFF Operate In?
Laboratorios Farmaceuticos Rovi, S.A. operates within the biotechnology industry, a sector characterized by rapid innovation, intense competition, and stringent regulatory oversight. The global biotechnology market is projected to reach $3.44 trillion by 2030, growing at a CAGR of 12.3% from 2022. Rovi competes with other pharmaceutical companies, including AKBLF (Akebia Therapeutics Inc), CAMRF (Camber Energy Inc), CSMYF (CMS Energy Corp), CZMWF (CZ BioTech), and GNNSF (Genus PLC). Rovi's focus on specialized medications and contract manufacturing services differentiates it from competitors.
Who Are LABFF's Key Customers?
- Wholesalers
- Doctors
- Nursing staff
- Pharmacists
- Patients
FY2026 estForward Outlook
Wall Street analysts project Laboratorios Farmaceuticos Rovi, S.A. revenue of about $768.1M for fiscal 2026, with EPS near $2.50. The estimate reflects 8 contributing analysts.
ROE 21%Key Financial Metrics
Return on equity for Laboratorios Farmaceuticos Rovi, S.A. stands at 20.9%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 14.2%, showing how much profit it generates from its asset base. LABFF trades at a trailing price-to-earnings ratio of 22.58, roughly in line with the Healthcare sector average of ~23x. Its free cash flow yield is 3.9%, a gauge of the cash the business throws off relative to its market value. A current ratio of 3.66 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 4.5%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 7/9Financial Health
Laboratorios Farmaceuticos Rovi, S.A.'s Piotroski F-Score is 7/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of 8.42 places it in the safe zone, indicating low near-term bankruptcy risk.
LABFF Valuation & Market Position
With a $4.63B market cap, Laboratorios Farmaceuticos Rovi, S.A. sits in the mid-cap segment of the market. Relative to its peer group, LABFF's quantitative score of 46/100 is roughly in line with the peer average of 55/100.
LABFF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Rovi's recent strategic partnerships suggest a strong commitment to expanding their market reach, potentially leading to increased revenue streams. This mirrors moves seen by companies like Moderna early in their vaccine development.
- Insider buying activity often signals management's confidence in the company's future prospects, suggesting they believe the stock is undervalued.
- Positive community sentiment indicates growing investor confidence in Rovi's long-term growth potential and strategic direction.
- Rovi's focus on specialized pharmaceutical manufacturing positions them well in a market increasingly demanding niche products, similar to how specialty chemical companies have thrived.
Bear Case
- Recent insider selling could indicate concerns about the company's near-term performance or potential headwinds, similar to concerns that arose before the 2008 financial crisis.
- Negative community sentiment suggests growing skepticism about Rovi's ability to meet market expectations or overcome competitive challenges.
- Increased regulatory scrutiny in the pharmaceutical sector could pose challenges for Rovi, impacting their profitability and growth prospects.
- Shifting market dynamics and increased competition from larger pharmaceutical players could erode Rovi's market share and pricing power.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
LABFF Latest News
-
Global Market Highlights 3 Stocks That May Be Trading Below Fair Value Estimates
Yahoo! Finance: LABFF News · May 26, 2026
LABFF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for LABFF.
Price Targets
Wall Street price target analysis for LABFF.
LABFF MoonshotScore
What does this score mean?
The MoonshotScore rates LABFF 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Juan Lopez-Belmonte Encina
Unknown
Information regarding Juan Lopez-Belmonte Encina's specific background and career history is not available in the provided data. Therefore, a detailed biography cannot be constructed. Further research would be needed to provide a comprehensive profile, including educational background, previous roles, and relevant credentials.
Track Record: Due to the limited information available, it is not possible to provide a detailed track record of Juan Lopez-Belmonte Encina's achievements and strategic decisions as CEO. Further research would be necessary to assess their performance and contributions to Laboratorios Farmaceuticos Rovi, S.A.
LABFF OTC Market Information
The OTC Other tier, where Laboratorios Farmaceuticos Rovi, S.A. trades, represents the lowest of the OTC market tiers. Companies in this tier often do not meet the minimum financial standards required for OTCQX or OTCQB, and may have limited or no reporting requirements. This tier includes companies that are unwilling or unable to provide current information to the public markets, often making it difficult for investors to assess their true financial health and operational status compared to companies listed on major exchanges like NYSE or NASDAQ.
- OTC Tier: OTC Other
- Limited Disclosure: The lack of readily available financial information increases investment risk.
- Low Liquidity: Reduced trading volume can lead to difficulty in buying or selling shares.
- Price Volatility: OTC stocks can experience significant price swings due to limited trading activity.
- Regulatory Scrutiny: OTC-listed companies may face increased regulatory scrutiny.
- Potential for Fraud: The OTC market has a higher risk of fraudulent activity compared to major exchanges.
- Verify the company's registration and legal standing.
- Review available financial statements and disclosures.
- Assess the company's business model and competitive landscape.
- Evaluate the management team and their track record.
- Understand the risks associated with investing in OTC stocks.
- Monitor trading volume and price activity.
- Consult with a financial advisor.
- Established Business Operations: Laboratorios Farmaceuticos Rovi, S.A. has been in operation since 1946.
- International Presence: The company operates in Spain, the European Union, and OECD countries.
- Partnership with Moderna: The collaboration with Moderna provides a degree of credibility.
- Positive Financial Metrics: The company has a positive profit margin and gross margin.
What Investors Ask About Laboratorios Farmaceuticos Rovi, S.A. (LABFF) — Healthcare
What does the AI Score mean for LABFF?
LABFF holds an AI Score of 46/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. Laboratorios Farmaceuticos Rovi, S.A. is a Spanish pharmaceutical company engaged in the research, development, production, and sale of pharmaceutical products. It operates internationally, with a …
What does Laboratorios Farmaceuticos Rovi, S.A. do?
Laboratorios Farmaceuticos Rovi, S.A. is a pharmaceutical company that researches, develops, produces, and sells pharmaceutical products. They operate in Spain, the European Union, OECD countries, and internationally. Rovi manufactures its own branded products, including low-molecular-weight heparins and contrast agents, and also provides contract manufacturing services to other pharmaceutical companies, producing various pharmaceutical forms like prefilled syringes and tablets.
What are the main risks for LABFF?
Laboratorios Farmaceuticos Rovi, S.A. faces several risks inherent to the pharmaceutical industry. Competition from generic drug manufacturers poses a threat to their branded products. Regulatory changes in pricing and market access could impact profitability. Economic downturns may reduce healthcare spending. Patent expirations on key drugs could decrease revenue.
What are the key factors to evaluate for LABFF?
Laboratorios Farmaceuticos Rovi, S.A. (LABFF) holds an AI score of 46/100 (low). P/E: 22.6x vs the S&P 500's ~20-25x. Not financial advice.
How frequently does LABFF data refresh on this page?
LABFF's price was last updated on Jul 23, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven LABFF's recent stock price performance?
Laboratorios Farmaceuticos Rovi, S.A. (LABFF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Diversified product portfolio. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider LABFF overvalued or undervalued right now?
Laboratorios Farmaceuticos Rovi, S.A. (LABFF) trades at 22.6x earnings. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research LABFF before investing?
Before investing in Laboratorios Farmaceuticos Rovi, S.A. (LABFF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding LABFF to a portfolio?
Key strength of Laboratorios Farmaceuticos Rovi, S.A. (LABFF): Diversified product portfolio. Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on provided data and may not be exhaustive.
- OTC market data may be less reliable than exchange-listed data.